

Draft Guidance on Doxycycline

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Doxycycline

Form/Route: Suspension/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-way, crossover *in-vivo*
Strength: EQ 25 mg/ 5mL
Subjects: Normal healthy males and females, general population
Additional Comments: Females should not be pregnant, and if applicable, should practice abstinence or contraception during the study.

2. Type of study: Fed
Design: Single-dose, two-way, crossover *in-vivo*
Strength: EQ 25 mg/ 5mL
Subjects: Normal healthy males and females, general population
Additional comments: Please see comment above.

Analytes to measure (in appropriate biological fluid): Doxycycline in plasma

Bioequivalence based on (90% CI): Doxycycline

Waiver request of in-vivo testing: Not applicable.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Please note that a dosage unit is based on the labeled concentration of the suspension product. This product is labeled as 25 mg/5 ml, hence the dosage unit is 5 ml. A total of 12 dosage units from 12 different bottles should be used. Specifications will be determined upon review of the application.